RPRX · Royalty Pharma PLC
Price
Snapshot
50 fields · last close| Market Cap | $35.80B |
| P/E | 43.93 |
| Float | 414.3M |
| Beta | 0.39 |
| Volatility | 9.8% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 83.8 |
| Price | 62.39 |
| Change | +0.22% |
| Prev Close | 62.25 |
| Open | 60.92 |
| Day Low | 60.78 |
| Day High | 62.42 |
| Avg Vol | 3 |
| Avg $ Vol | $203.7M |
| 52W High | 64.38 |
| 52W Low | 35.91 |
| 52W Pos | 93.0% |
| From High | −3.09% |
| From Low | +73.72% |
| Max DD 1Y | −12.12% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +7.26% |
| SMA 50 | +4.97% |
| SMA 200 | +19.41% |
| RSI (14) | 66.0 |
| Vol 30D | 23.6% |
| Vol 90D | 25.6% |
| 1Y Range | 36–64 |
| Daily bars | 538 |
| Perf Week | +10.04% |
| Perf Month | +6.52% |
| Perf Quarter | +6.01% |
| Perf Half Y | +25.81% |
| Perf Year | +68.20% |
| Perf YTD | +60.55% |
| Prev Day | +0.22% |
| Clavix | A |
| Debt / Eq | 1.38 |
| Curr Ratio | 2.40 |
| Int Cover | 6.4× |
| FCF Margin | — |
| Rev Growth | +5.1% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 2 / 14 |
Clavix risk grade
regraded every trading dayRPRX grades A, 83.8 of 100. Steadiest on Macro Resilience (72), most exposed on Sector Resilience (60, mixed). 3 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 2 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| RPRX | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.39 | 0.44 |
| Volatilityannualized | 9.8% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −12.1% | — |
| Typical daily movemedian absolute daily change | 0.95% | — |
| Days beyond ±3%of the last 252 sessions | 14 (6%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| RPRX | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.39 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| RPRX | |
|---|---|
| 1 week | +10.0% |
| 1 month | +6.5% |
| Year to date | +60.6% |
| 1 year | +68.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| RPRX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 31 Jul |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 7 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 7 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| RPRX | |
|---|---|
| Revenue growthyear over year | +5.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openRoyalty Pharma's board approved a quarterly dividend of $0.235 per Class A ordinary share for Q4 2026, payable on December 10, 2026 to shareholders of record on November 13, 2026.
Royalty Pharma's board approved a fourth-quarter 2026 dividend of $0.235 per Class A ordinary share. The announcement was made on October 16, 2026.
Royalty Pharma EVP Marshall Urist sold 4,126 shares of company stock on September 28th at an average price of $57.88, totaling about $238,813. The sale cut his direct ownership in half and was made under a pre-arranged trading plan.
Wall Street Zen lowered its rating on Royalty Pharma from 'strong-buy' to 'buy'. The article also notes that Goldman Sachs reiterated a 'buy' rating with a $66.00 target price, though the rest of the analyst commentary is cut off.
Wall Street Zen downgraded its rating on Royalty Pharma from "strong-buy" to "buy" in a Saturday report. The article is very short and provides no further detail or context.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $13.88B | 14.75 | 0.37 | Compare |
| CORT | Corcept Therapeutics Inc | C | $12.59B | 228.66 | 0.52 | Compare |
| ELAN | Elanco Animal Health Inc | B | $11.34B | — | 1.75 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $126.0B | 13.52 | 0.19 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | — | $9.01B | — | 0.45 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $8.36B | — | 0.81 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.